Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial

IMPORTANCE: The drug HD201 is a biosimilar candidate for breast cancer treatment as the reference trastuzumab. OBJECTIVE: To compare the efficacy of HD201 with referent trastuzumab. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial (TROIKA) included 502 women with ERBB2-positive earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivot, Xavier, Georgievich, M. A., Shamrai, Volodymyr, Dzagnidze, Giorgi, Soo Hoo, Hwoei Fen, Kaewkangsadan, Viriya, Petrelli, Fausto, Villanueva, Cristian, Nikolaevich, Lipatov O., Hii, Jocelyn, Kim, Jamie, Pradhan, Sumita, Jaison, Litha, Feyaerts, Peggy, Kaufman, Leonard, Derde, Marie-Paule, Bonamy, Ghislain M. C., Deforce, Filip, Cox, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895313/
https://www.ncbi.nlm.nih.gov/pubmed/35238873
http://dx.doi.org/10.1001/jamaoncol.2021.8171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895313/
https://www.ncbi.nlm.nih.gov/pubmed/35238873
http://dx.doi.org/10.1001/jamaoncol.2021.8171

Ejemplares similares